ClinicalTrials.gg
RecruitingNCT07441824PERiANPUpdated May 5, 2026

Pancreatic Enzyme Replacement in Acute Necrotizing Pancreatitis

A Phase 3 interventional study of Pancreatic enzyme capsules and Placebo in Acute Necrotizing Pancreatitis and Pancreatic Exocrine Insufficiency, sponsored by Asian Institute of Gastroenterology, India. Recruiting at 4 sites in India. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Asian Institute of Gastroenterology, India · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

In this multicenter, double blinded, placebo-controlled, 1:1 parallel group RCT, the investigators propose to evaluate the impact of pancreatic exocrine replacement therapy on patients with acute necrotizing pancreatitis (ANP). The investigators will include patients of 18-60yrs age and both genders with >50% pancreatic parenchymal necrosis and at least 5% loss of body weight.

The primary outcome measure is percent change in body weight at 3 months after enrolment. The intervention will include pancreatic enzyme consisting of 25000 IU of lipase and similar appearing placebo.

Read the detailed description

Acute pancreatitis (AP), an inflammatory disorder of the pancreas, is mild and self-limiting in most patients. Around 10-20% of AP patients develop acute necrotizing pancreatitis (ANP) which is characterized by destruction of both pancreatic and peripancreatic tissue and is associated with high rate of morbidity and mortality due to both local and systemic complications.

Early recognition and close monitoring of affected patients is crucial. Treatment consists of goal-directed intravenous fluid resuscitation, pain control, and enteral nutrition as early as possible. While sterile necrosis might resolve with above conservative measures, infected necrosis requires antibiotics and further interventions such as percutaneous drainage, minimally invasive surgeries, and endoscopic necrosectomy.

In ANP patients there is direct destruction of acinar tissue that results in pancreatic exocrine insufficiency (PEI). In PEI there is insufficient secretion of pancreatic enzymes that causes inadequate nutrient digestion and absorption resulting in weight loss, malnutrition, metabolic bone disease and fat-soluble vitamins and mineral deficiencies. The risk of PEI after ANP is about 25% over 3 years. According to two meta-analysis, PEI was found to be more prevalent during the index AP episode and it remained persistent in about half of the study population at follow-ups. They also reported that the risk of developing PEI is more in those with alcoholic etiology and severe and necrotizing pancreatitis. Hence, management of PEI following ANP is important to improve nutritional status and quality of life. Pancreatic enzyme replacement therapy (PERT) is the mainstay of treatment for PEI. While the use of PERT is well-established in chronic pancreatitis, its efficacy in patients with ANP is still unclear. Hence, in this study, the investigators aim to provide insights into the potential benefits of enzyme supplementation in patients with ANP by evaluating nutritional status, clinical outcomes, and quality of life.

This is a multicenter, double blinded, placebo-controlled, 1:1 parallel group RCT, the investigators propose to evaluate the impact of pancreatic exocrine replacement therapy on patients with acute necrotizing pancreatitis (ANP). The investigators will include patients of 18-60yrs age and both genders with >50% pancreatic parenchymal necrosis and at least 5% loss of body weight.

The primary outcome measure is percent change in body weight at 3 months after enrolment. The intervention will include pancreatic enzyme consisting of 25000 IU of lipase and similar appearing placebo.

02

Conditions studied

  • Acute Necrotizing Pancreatitis
  • Pancreatic Exocrine Insufficiency

Keywords

  • acute pancreatitis
  • pancrearic exocrine insufficiency
  • pancreatic enzyme replacement therapy
03

In context

Pancreatitis, Acute Necrotizing

75 studies on the registry are indexed under Pancreatitis, Acute Necrotizing; 20 are open to participants now.

This study's planned enrollment of 140 is above the median of 70 across 47 interventional studies indexed under Pancreatitis, Acute Necrotizing.

Browse Pancreatitis, Acute Necrotizing studies →

Lead sponsor

Asian Institute of Gastroenterology, India is the lead sponsor of 135 studies on the registry; 59 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with AP according to the Revised Atlanta Classification diagnostic criteria
  • Index episode of acute pancreatitis with more than 50% pancreatic parenchymal necrosis and at least 5% loss of pre pancreatitis body weight at the time of screening
  • Within 6 weeks of onset of disease
  • Able to take food orally
  • Age 18-60 years
  • Both genders

Exclusion criteria

Exclusion Criteria:

  • Underlying chronic pancreatitis
  • Recurrent acute pancreatitis
  • Pancreatic cancer
  • Patients being discharged with NJ tubes
  • Pregnancy and lactation
  • Inability to give .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Enteric coated enzyme preparation containing: Lipase 25000U, Amylase 18000U, Protease 1000U. These m

    Drug: Pancreatic enzyme capsules

  • Placebo comparator
    Similar appearing glucose capsules will be provided three times a day along with food

    Drug: Placebo Similar appearing glucose capsules

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percent change in body weight

    Body weight (in kg) will be measured at baseline and again at 3 months follow-up, and the difference between the two time points will be used to assess the effect of the intervention on patients' weight status. The change will be expressed as percent change of weight 3 months compared to baseline weight.

    Time frame: 3 months

Secondary outcomes

  1. Change in quality of life

    Quality of life will be assessed by the Short Form (SF)-36 tool. This is a standardised and validated questionnaire based scoring tool that contains 36 questions dealing with 8 domains of quality of life. The lowest score in this tool is 0 and the highest score is 100, a higher score indicating better quality of life.

    Time frame: 3 months

  2. Change in pancreatic exocrine function

    Exocrine function will be assessed by the Fecal elastase test and will be expressed as microgram of elastase per gram of stool. Higher value indicates better exocrine function. The cut-off value that will be used is 200mcg/gm elastase, below which exocrine insufficiency will be considered to be present.

    Time frame: 3 months

  3. Change in nutritional status: Subjective Global Assesment (SGA)

    This is a semiquantitative questionnaire based nutritional assessment tool which classifies the nutritional status as SGA A (normal nutrition), SGA B (mild/moderate malnutrition) and SGC C (severe malnutrition)

    Time frame: 3 months

  4. Change in nuritional status: Anthropometry

    Skin fold thickness (in mm) over the triceps muscle at the mid arm level.

    Time frame: 3 months

  5. Change in nutritional change: Anthropometry

    Mid-arm circumference (MAC) in cm.

    Time frame: 3 months

  6. Change in nutritional status: Anthropometry

    Mid-upper arm muscle circumference (MAMC) in cm.

    Time frame: 3 months

  7. Change in nutritional status: Anthropomentry

    Mid-arm muscle area (MAMA) in cm square.

    Time frame: 3 months

  8. Change in nutritional status: Biochemical assessment

    Hemoglobin in gm/dL

    Time frame: 3 months

  9. Change in nutritional status: Biochemical assessment

    Serum prealbumin in mg/dL

    Time frame: 3 months

  10. Change in nutritional status: Biochemical assessment

    Vitamin D

    Time frame: 3 months

  11. Change in nutritional status: Biochemical assessment

    Vitamin B12

    Time frame: 3 months

  12. Change in the endocrine status

    Fasting blood glucose (FBS)

    Time frame: 3 months

  13. Change in the endocrine status

    HbA1c

    Time frame: 3 months

  14. Change in the endocrine status

    Stimulated C-peptide

    Time frame: 3 months

  15. Change in patient's impression of change after treatment

    This will be evaluated using the Patient's Global Impression of Change (PGIC). The score ranges from 1-7, with a score of 1 indicating very much improved and 7 indicating very much worse

    Time frame: 3 months

  16. Readmission after onset of treatment

    Readmission to hospital

    Time frame: 3 months

Other outcomes

  1. Change in body composition (Bioimpedence analysis): Body fat mass (kg)

    Total body fat will be assessed using Bioimpedence analysis (BIA) This is a non-invasive method that operates by sending a low-level, imperceptible electrical current through the body. The normal range is 10-20kg.

    Time frame: 3 months

  2. Change in body composition (Bioimpedence analysis): Skeletal muscle mass (kg)

    Skeletal muscle mass will be assessed using Bioimpedence analysis (BIA) This is a non-invasive method that operates by sending a low-level, imperceptible electrical current through the body.

    Time frame: 3 months

  3. Change in body composition (Bioimpedence analysis): Total body water (litres)

    Total body water will be quantified using Bioimpedence analysis (BIA) This is a non-invasive method that operates by sending a low-level, imperceptible electrical current through the body.

    Time frame: 3 months

  4. Change in body composition (Bioimpedence analysis): Phase angle at 50kH (degrees)

    Cell membrane integrity will be assessed using the phase angle function of Bioimpedence analysis (BIA) This is a non-invasive method that operates by sending a low-level, imperceptible electrical current through the body.

    Time frame: 3 months

  5. Change in body composition (Bioimpedence analysis): Visceral fat level (numerical unit; normal range (1-12).

    Visceral fat level will be assessed using Bioimpedence analysis (BIA) This is a non-invasive method that operates by sending a low-level, imperceptible electrical current through the body. The normal range is from 1-12, a loser value indicating lower visceral fat and higher value indicates larger visceral fat.

    Time frame: 3 months

07

Study locations

4 of 4 sites recruiting
  • Gauhati Medical College
    Guwahati, Assam 781032, India
    Recruiting
  • Asian Institute of Gastroenterology Hospitals, Gachibowli
    Hyderabad, Telangana 500032, India
    Recruiting
  • Asian Institute of Gastroenterology, Banjara Hills
    Hyderabad, Telangana 500082, India
    Recruiting
  • ILS Hospital, Dum Dum
    Kolkata, West Bengal 700080, India
    Recruiting
08

References and documents

Publications

  • Wang GJ, Gao CF, Wei D, Wang C, Ding SQ. Acute pancreatitis: etiology and common pathogenesis. World J Gastroenterol. 2009 Mar 28;15(12):1427-30. doi: 10.3748/wjg.15.1427. PubMed 19322914 ↗
  • Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, Tsiotos GG, Vege SS; Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013 Jan;62(1):102-11. doi: 10.1136/gutjnl-2012-302779. Epub 2012 Oct 25. PubMed 23100216 ↗
  • Lee PJ, Papachristou GI. New insights into acute pancreatitis. Nat Rev Gastroenterol Hepatol. 2019 Aug;16(8):479-496. doi: 10.1038/s41575-019-0158-2. PubMed 31138897 ↗
  • Umapathy C, Raina A, Saligram S, Tang G, Papachristou GI, Rabinovitz M, Chennat J, Zeh H, Zureikat AH, Hogg ME, Lee KK, Saul MI, Whitcomb DC, Slivka A, Yadav D. Natural History After Acute Necrotizing Pancreatitis: a Large US Tertiary Care Experience. J Gastrointest Surg. 2016 Nov;20(11):1844-1853. doi: 10.1007/s11605-016-3264-2. Epub 2016 Sep 12. PubMed 27619808 ↗
  • Huang W, de la Iglesia-Garcia D, Baston-Rey I, Calvino-Suarez C, Larino-Noia J, Iglesias-Garcia J, Shi N, Zhang X, Cai W, Deng L, Moore D, Singh VK, Xia Q, Windsor JA, Dominguez-Munoz JE, Sutton R. Exocrine Pancreatic Insufficiency Following Acute Pancreatitis: Systematic Review and Meta-Analysis. Dig Dis Sci. 2019 Jul;64(7):1985-2005. doi: 10.1007/s10620-019-05568-9. Epub 2019 Jun 4. PubMed 31161524 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Jun 2027, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2026
First posted
Mar 2, 2026
StartActual
Apr 10, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07441824
Responsible party
Rupjyoti Talukdar (Director, Pancreatology, AIG Hospitals, Asian Institute of Gastroenterology, India) — Principal investigator
First posted
Mar 2, 2026
Start date
Apr 10, 2026
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
May 5, 2026

Study contacts

Abdul Rasheed, PharmD
Contact
abdulrasheedmd1223@gmail.com
+919652104726
Rupjyoti Talukdar, MD
study director · Asian Institute of Gastroenterology Hospitals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pancreatic Enzyme

Start the discussion